COPENHAGEN, Denmark, Sept. 29, 2026 -- Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announced the successful close of...
Pappas Ventures closes on fourth fund
News | 03. 10. 2009
RESEARCH TRIANGLE PARK, N.C., March 10, 2009 — Pappas Ventures today announced the final closing of its fourth fund, a $102 million venture capital fund focused on the life sciences sector. Like its immediate predecessor funds, Pappas Ventures IV will invest in product-oriented biopharmaceutical companies, with a secondary focus on medical technologies.
